| Literature DB >> 19174997 |
Takehiko Ogawa1, Hiroji Uemura, Futoshi Sano, Kouji Hoshino, Kaoru Kita, Narihiko Hayashi, Masayo Kagota, Takayuki Murakami, Kazuhide Makiyama, Yasuhide Miyoshii, Noboru Nakaigawa, Masahiro Yao, Hidetoshi Shimura, Akihiko Furuhata, Naoya Fujikawa, Koichi Shioi, Teiichiro Ueki, Yoshinori Hara, Kiyoshi Saitou, Satoshi Kawakami, Yoshiaki Satomi, Yusuke Hattori, Junichi Teranishi, Keiichi Kondo, Takeshi Kishida, Kazuo Saito, Kazumi Noguchi, Hiroshi Fuji, Toyoaki Yamaguchi, Yuzo Kinoshita, Sakae Nomura, Minoru Yoshida, Naoki Sakai, Hideyuki Terao, Tatsuya Matsumoto, Susumu Umemoto, Yoshiharu Ogo, Kazuki Kobayashi, Sumio Noguchi, Tomoyuki Asakura, Teruo Kohdaira, Kozue Iguchi, Koji Izumi, Masami Hirano, Hitomi Kanno, Toshihiro Takahashi, Fumihiko Nukui, Yasuhiro Mokuo, Kentaro Muraoka, Yutaka Osada, Makoto Funahashi, Kazuo Kitami, Shimpei Sugiura, Junichi Ohta, Takeshi Miura, Yoshio Ishibashi, Mitsunobu Masuda, Atsushi Komiya, Yutaka Suwa, Takafumi Hashiba, Kunihisa Mitaka, Masataka Kobayashi, Kimito Ohsaka, Takano Futoshi, Tetsuzo Tsuchiya, Akira Iwasaki, Yuzo Yamashita, Junichi Matsuzaki, Yoshinobu Kubota.
Abstract
Silodosin (URIEF), a new so-called 3rd generation alpha-1 blocker, is widely expected to be effective and useful for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), due to its high specificity to alpha-1A receptor. We evaluated the efficacy of Silodosin, on 187 males 50 years old or over with the diagnosis of BPH. Silodosin significantly improved the International Prostate Symptom Score (IPSS) and quality of life (QOL) score from the day after administration was started. Among 166 patients whose data were available for the analysis of efficacy of Silodosin, 77.5% showed apparent subjective improvement. Eighty three patients, who had been taking another alpha-1 blocker but without satisfactory effects, showed almost the same improvements in IPSS and QOL score after switching to Silodosin as the remaining 83 patients who had no preceding treatment with an alpha-1 blocker. The improvements were not only in voiding symptoms but also in storage symptoms. The patients, who had serious storage symptoms, responded rather well to Silodosin and showed significant improvement. Taken together, Silodosin showed a quick effect for improving subjective symptoms and QOL, and was found to be useful for the management of LUTS with BPH.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19174997
Source DB: PubMed Journal: Hinyokika Kiyo ISSN： 0018-1994